Sep 112012

The Hygiology Post is presenting information about a company that seems to have much potential to help many people. 2012 may be a pivotal year in determining how helpful the patented technologies may actually be for people.    

Senesco Technologies has continued to update information on its web site (; obtained on 9-10-12). As a matter of disclosure : The author continues to be a current shareholder in the company.

 The Senesco Technologies web site (; obtained on 9-10-12) has posted relevant information about its research. Here is an excerpt:


Combining SNS01-T with Bortezomib Significantly Increases Its Effectiveness in Model of Multiple Myeloma

BRIDGEWATER, N.J. (September 10th, 2012) – Senesco Technologies, Inc. (‘Senesco’ or the ‘Company’) (NYSE MKT: SNT) announced today that the combination of bortezomib (the active component of VELCADE® marketed by Millennium, The Takeda Oncology Company) and SNS01-T, the subject of Senesco’s on-going multiple myeloma clinical study, performs significantly better than either treatment alone in mouse xenograft models.

‘We are very pleased to have shown that SNS01-T enhances the ability of bortezomib to inhibit tumor growth in the mouse model and could be a way to lower the dose and reduce the severity of treatment-related side effects of bortezomib ,’ said Leslie J. Browne, Ph.D., President and CEO of Senesco. Dr. Browne added, ‘Since treatment increasingly involves combination therapy, it is important that SNS01-T works well when added to current multiple myeloma drugs.’ ”

The Hygiology Post welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.


Louis DeCola, Jr.                                    © 2012 The Hygiology Post